Loading...

Cosmo Pharmaceuticals

OTCPK:CMOP.F
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CMOP.F
OTCPK
CHF1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print
CMOP.F Share Price and Events
7 Day Returns
0%
OTCPK:CMOP.F
-1.2%
US Pharmaceuticals
-0.7%
US Market
1 Year Returns
-
OTCPK:CMOP.F
8.5%
US Pharmaceuticals
3%
US Market
CMOP.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cosmo Pharmaceuticals (CMOP.F) 0% 0% - - - -
US Pharmaceuticals -1.2% -1.3% -3.2% 8.5% 10.2% 16.5%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • No trading data on CMOP.F.
  • No trading data on CMOP.F.
Price Volatility
CMOP.F
Industry
5yr Volatility vs Market

Value

 Is Cosmo Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cosmo Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cosmo Pharmaceuticals.

OTCPK:CMOP.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:CMOP.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 7.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.643 (1 + (1- 12.5%) (12.15%))
0.807
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.807 * 7.14%)
8.49%

Discounted Cash Flow Calculation for OTCPK:CMOP.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cosmo Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:CMOP.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 8.49%)
2019 -16.30 Analyst x2 -15.02
2020 26.50 Analyst x2 22.52
2021 50.00 Analyst x2 39.16
2022 192.00 Analyst x1 138.60
2023 335.00 Analyst x1 222.90
2024 465.09 Est @ 38.83% 285.25
2025 595.32 Est @ 28% 336.56
2026 716.89 Est @ 20.42% 373.57
2027 825.24 Est @ 15.11% 396.38
2028 919.30 Est @ 11.4% 407.01
Present value of next 10 years cash flows €2,206.91
OTCPK:CMOP.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €919.30 × (1 + 2.73%) ÷ (8.49% – 2.73%)
€16,398.93
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €16,398.93 ÷ (1 + 8.49%)10
€7,260.43
OTCPK:CMOP.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,206.91 + €7,260.43
€9,467.35
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €9,467.35 / 14.84
€744.56
OTCPK:CMOP.F Discount to Share Price
Calculation Result
Exchange Rate EUR/CHF
(Reporting currency to currency of SWX:COPN)
1.129
Value per Share
(CHF)
= Value per Share in EUR x Exchange Rate (EUR/CHF)
= €638.15 x 1.129
CHF720.27
Non-primary Listing Adjustment Factor 1 share in OTCPK:CMOP.F represents 0.85707x of SWX:COPN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85707x
Value per Share
(Listing Adjusted, USD)
= Value per Share (CHF) x Listing Adjustment Factor
= CHF 720.27 x 0.85707
$617.33
Value per share (USD) From above. $617.33
Current discount Discount to share price of $84.85
= -1 x ($84.85 - $617.33) / $617.33
86.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cosmo Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $84.85 vs Future cash flow value of $617.33
Current Discount Checks
For Cosmo Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cosmo Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cosmo Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cosmo Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cosmo Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CMOP.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.20
SWX:COPN Share Price ** SWX (2019-02-20) in CHF CHF99
SWX:COPN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.886 €87.71
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 28 Publicly-Listed Pharmaceuticals Companies 22.57x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cosmo Pharmaceuticals.

OTCPK:CMOP.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:COPN Share Price ÷ EPS (both in EUR)

= 87.71 ÷ -1.20

-73.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cosmo Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Cosmo Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cosmo Pharmaceuticals's expected growth come at a high price?
Raw Data
OTCPK:CMOP.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -73.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
63.2%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.72x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cosmo Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cosmo Pharmaceuticals's assets?
Raw Data
OTCPK:CMOP.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €29.91
SWX:COPN Share Price * SWX (2019-02-20) in CHF CHF99
SWX:COPN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.886 €87.71
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 180 Publicly-Listed Pharmaceuticals Companies 3.44x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
OTCPK:CMOP.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:COPN Share Price ÷ Book Value per Share (both in EUR)

= 87.71 ÷ 29.91

2.93x

* Primary Listing of Cosmo Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cosmo Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Cosmo Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cosmo Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cosmo Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cosmo Pharmaceuticals expected to grow at an attractive rate?
  • Cosmo Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Cosmo Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Cosmo Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:CMOP.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:CMOP.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 63.2%
OTCPK:CMOP.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 36.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.1%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CMOP.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CMOP.F Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 493 233 190 2
2022-12-31 280 114 103 3
2021-12-31 174 42 35 5
2020-12-31 118 17 -1 5
2019-12-31 60 -10 -23 3
OTCPK:CMOP.F Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 67 -10 -18
2018-09-30 70 -11 -20
2018-06-30 72 -13 -23
2018-03-31 70 -11 -28
2017-12-31 68 -9 -32
2017-09-30 68 -6 -18
2017-06-30 69 -2 -4
2017-03-31 69 10 8
2016-12-31 68 22 19
2016-09-30 70 18 18
2016-06-30 72 14 16
2016-03-31 66 -13 132

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cosmo Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Cosmo Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CMOP.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Cosmo Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CMOP.F Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 12.50 17.70 7.30 2.00
2022-12-31 6.90 9.68 4.83 3.00
2021-12-31 1.90 4.48 0.46 4.00
2020-12-31 0.29 1.75 -1.13 4.00
2019-12-31 -1.55 -1.49 -1.65 3.00
OTCPK:CMOP.F Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.20
2018-09-30 -1.36
2018-06-30 -1.53
2018-03-31 -1.86
2017-12-31 -2.19
2017-09-30 -1.23
2017-06-30 -0.25
2017-03-31 0.56
2016-12-31 1.37
2016-09-30 1.26
2016-06-30 1.15
2016-03-31 9.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cosmo Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Cosmo Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cosmo Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cosmo Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cosmo Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cosmo Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cosmo Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cosmo Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cosmo Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cosmo Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CMOP.F Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 66.50 -18.01 50.64 10.39
2018-09-30 69.51 -20.49 52.34 9.67
2018-06-30 72.42 -22.97 54.03 8.95
2018-03-31 70.02 -27.71 50.16 9.00
2017-12-31 67.71 -32.45 46.28 9.05
2017-09-30 68.26 -17.99 38.40 8.78
2017-06-30 68.81 -3.53 30.52 8.51
2017-03-31 68.60 7.91 23.09 8.00
2016-12-31 68.39 19.34 15.66 7.49
2016-09-30 70.34 17.80 12.85 10.43
2016-06-30 72.28 16.26 10.04 13.36
2016-03-31 66.46 132.23 16.45 18.22
2015-12-31 60.63 248.19 22.87 23.08
2015-09-30 59.59 241.11 25.74 23.18
2015-06-30 58.55 234.04 28.60 23.27
2015-03-31 69.10 153.68 22.64 21.24
2014-12-31 79.64 73.32 16.67 19.22
2014-09-30 75.78 77.76 13.51 20.11
2014-06-30 71.91 82.20 10.35 21.01
2014-03-31 64.65 75.47 9.02 19.31
2013-12-31 57.39 68.73 7.69 17.60
2013-09-30 51.40 66.35 7.42 14.94
2013-06-30 45.41 63.96 7.15 12.27
2013-03-31 52.51 41.64 6.57 11.59
2012-12-31 59.60 19.32 5.98 10.92
2012-09-30 58.82 21.03 6.09 9.04
2012-06-30 58.05 22.72 6.21 7.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cosmo Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cosmo Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cosmo Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cosmo Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cosmo Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cosmo Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cosmo Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cosmo Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cosmo Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cosmo Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cosmo Pharmaceuticals Company Filings, last reported 4 months ago.

OTCPK:CMOP.F Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 444.85 158.15 349.44
2018-09-30 444.85 158.15 349.44
2018-06-30 456.37 4.26 187.10
2018-03-31 456.37 4.26 187.10
2017-12-31 470.12 4.48 172.70
2017-09-30 470.12 4.48 172.70
2017-06-30 480.71 4.93 177.57
2017-03-31 480.71 4.93 177.57
2016-12-31 415.56 5.31 166.49
2016-09-30 415.56 5.31 166.49
2016-06-30 414.41 7.42 133.54
2016-03-31 414.41 7.42 133.54
2015-12-31 403.65 8.13 116.34
2015-09-30 403.65 8.13 116.34
2015-06-30 391.74 9.96 47.17
2015-03-31 391.74 9.96 47.17
2014-12-31 152.29 10.93 59.46
2014-09-30 152.29 10.93 59.46
2014-06-30 174.40 10.82 53.47
2014-03-31 174.40 10.82 53.47
2013-12-31 220.16 11.75 168.16
2013-09-30 220.16 11.75 168.16
2013-06-30 182.33 12.65 95.15
2013-03-31 182.33 12.65 95.15
2012-12-31 124.60 12.84 27.30
2012-09-30 124.60 12.84 27.30
2012-06-30 108.30 1.78 31.89
  • Cosmo Pharmaceuticals's level of debt (35.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (5.3% vs 35.6% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Cosmo Pharmaceuticals's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Cosmo Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cosmo Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cosmo Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cosmo Pharmaceuticals dividends. Estimated to be 0.51% next year.
If you bought $2,000 of Cosmo Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cosmo Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cosmo Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CMOP.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:CMOP.F Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 1.30 2.00
2022-12-31 0.73 3.00
2021-12-31 0.52 5.00
2020-12-31 0.30 5.00
2019-12-31 0.00 5.00
OTCPK:CMOP.F Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-29 0.000 0.000
2018-07-26 0.000 0.000
2017-05-26 1.500 1.258
2016-07-29 1.400 0.923
2014-03-27 1.000 0.748

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cosmo Pharmaceuticals has not reported any payouts.
  • Unable to verify if Cosmo Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cosmo Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cosmo Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Cosmo Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Cosmo Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cosmo Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cosmo Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cosmo Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alessandro Della Chà
COMPENSATION €1,671,169
AGE 55
TENURE AS CEO 5.2 years
CEO Bio

Mr. Alessandro E. Della Chà, LL.M, has been the Chief Executive Officer of Cosmo Pharmaceuticals N.V. (formerly Cosmo Pharmaceuticals S.p.A) since March 27, 2014 and also has been its Executive Director since 2006. Mr. Chà served as a Senior Partner at Studio Legale Edoardo Ricci e Associati, Milan until March 27, 2014. He specialized in company law, mergers and acquisitions. He joined the Studio Legale Edoardo Ricci e Associati in 1988. He served as an Assistant of the Central Director for Corporate Matters of Fininvest Group from 1987 to 1988. He served as the Non-Executive Vice Chairman of Cosmo Pharmaceuticals N.V. He served as a Director of Santarus, Inc. from April 10, 2012 to January 2, 2014. He served as a Director of II.PP.A.B. Milan (ex-ECA), from 1994 to 1998 a charitable institution owning hospitals and specialized in elderly care. He is Lecturer in conferences and seminars held by universities and institutions on commercial and company law issues. Mr. Chà has a Degree in Law from the University of Milan (ITA) and an LL.M. from the University of Leicester (GBR) in European Union Commercial Law.

CEO Compensation
  • Alessandro's compensation has been consistent with company performance over the past year.
  • Alessandro's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cosmo Pharmaceuticals management team in years:

6.4
Average Tenure
61
Average Age
  • The average tenure for the Cosmo Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mauro Ajani

TITLE
Founder & Chairman
AGE
63
TENURE
13.3 yrs

Alessandro Della Chà

TITLE
CEO & Executive Director
COMPENSATION
€2M
AGE
55
TENURE
5.2 yrs

Giuseppe Cipriano

TITLE
Chief Operating Officer
AGE
61
TENURE
18.3 yrs

Luigi Moro

TITLE
Chief Scientific Officer
AGE
67
TENURE
19.7 yrs

Chris Tanner

TITLE
Head of Transactions Office & Executive Director
COMPENSATION
€781K
AGE
67
TENURE
3 yrs

Niall Donnelly

TITLE
Chief Financial Officer
AGE
44
TENURE
2.9 yrs

Davide Malavasi

TITLE
Technical Director
AGE
45
TENURE
7.7 yrs

John Manieri

TITLE
Head of Investor Relations

Blake Boland

TITLE
Chief Sales Officer
AGE
58
TENURE
2.6 yrs

Massimo Pedrani

TITLE
Head of Generics Business Development
AGE
64
Board of Directors Tenure

Average tenure and age of the Cosmo Pharmaceuticals board of directors in years:

10.2
Average Tenure
61
Average Age
  • The average tenure for the Cosmo Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Mauro Ajani

TITLE
Founder & Chairman
AGE
63
TENURE
7.1 yrs

Alessandro Della Chà

TITLE
CEO & Executive Director
COMPENSATION
€2M
AGE
55
TENURE
13.3 yrs

Chris Tanner

TITLE
Head of Transactions Office & Executive Director
COMPENSATION
€781K
AGE
67
TENURE
13.3 yrs

Dieter Enkelmann

TITLE
Non-Executive Director
COMPENSATION
€156K
AGE
59
TENURE
13.3 yrs

Kevin Donovan

TITLE
Non-Executive Director
COMPENSATION
€140K
AGE
59
TENURE
3.2 yrs

Geert D’Haens

TITLE
Member of Scientific Advisory Board

William Sandborn

TITLE
Member of Scientific Advisory Board

Silvio Danese

TITLE
Member of Scientific Advisory Board

Maria Roncarolo

TITLE
Non-Executive Director
COMPENSATION
€156K
AGE
64
TENURE
7.1 yrs

Ralf Kiesslich

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Cosmo Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cosmo Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon. The company also provides Eleview, a submucosal injectable composition for extracting polyps and adenomas; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous lesion detection during colonoscopies; and Aemcolo, a pharmaceutical product used for the treatment of bacterial infections of the colon, such as traveler’s diarrhea, infectious colitis, clostridium difficile associated disease, and diverticulitis, as well as for treatment of inflammatory bowel diseases and hepatic encephalopathy. In addition, it offers Qolotag, a medical device that enhances the detection of lesions during sigmoidoscopies; Remimazolam, an ultra-short-acting sedative/anesthetic. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Details
Name: Cosmo Pharmaceuticals N.V.
CMOP.F
Exchange: OTCPK
Founded: 1997
CHF1,452,309,961
14,835,713
Website: http://www.cosmopharma.com
Address: Cosmo Pharmaceuticals N.V.
Riverside II,
Sir John Rogerson’s Quay,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX COPN New Common Shares SIX Swiss Exchange CH CHF 09. Mar 2007
OTCPK CMOP.F New Common Shares Pink Sheets LLC US USD 09. Mar 2007
DB C43 New Common Shares Deutsche Boerse AG DE EUR 09. Mar 2007
LSE 0RGI New Common Shares London Stock Exchange GB CHF 09. Mar 2007
BATS-CHIXE COPNZ New Common Shares BATS 'Chi-X Europe' GB CHF 09. Mar 2007
Number of employees
Current staff
Staff numbers
306
Cosmo Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 02:29
End of day share price update: 2019/02/20 00:00
Last estimates confirmation: 2019/05/14
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.